Core Insights - Jinbo Bio reported a revenue of 1.296 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 31.1% [1] - The net profit attributable to shareholders for the same period was 568 million yuan, showing a year-on-year growth of 9.29% [1] - In the third quarter alone, the company achieved a revenue of 437 million yuan, which is a year-on-year increase of 13.36% [1] - However, the net profit for the third quarter decreased by 16.24% to 176 million yuan compared to the same period last year [1] - Following the earnings report, Jinbo Bio's stock price fell sharply, dropping over 7% at one point on October 30 [1]

Group 1 - The report highlights the positive signals from the speeches at the 2025 Financial Street Forum regarding the construction of the Beijing Stock Exchange (BSE) and the New Third Board market [3] - The introduction of the North Exchange 50 ETF is expected to bring in approximately 16.1 billion yuan in incremental funds, with a comparison to the successful launch of the Sci-Tech 50 ETF [3] - The report emphasizes the importance of ETFs in enhancing market liquidity, with the Sci-Tech 50 ETF accounting for an average of 15.4% of total trading volume since its launch [3][4] Group 2 - The report suggests promoting long-term capital inflow by establishing more public fund products focused on small and medium-sized stocks, with an estimated 1 billion yuan in incremental funds awaiting entry into the market [3] - The establishment of specialized indices for the BSE is anticipated to generate around 5 billion yuan in additional funds, with several thematic public offerings expected to open for subscription [3] - The report indicates that the BSE will maintain a regular issuance rhythm, with an expectation of one new listing per week, which could provide investment opportunities in the new stock market [3] Group 3 - The report discusses the optimization of the listing standards for the BSE, which may open pathways for unprofitable companies to list, thus enhancing investment opportunities [3] - It highlights the potential for mergers and acquisitions as a growth path for small and medium enterprises, suggesting that the BSE could see increased activity in this area [3] - The report also mentions the need for improved trading mechanisms and the enhancement of the bond market product system at the BSE [3]

Core Insights - Aimeike is a leading player in the domestic medical aesthetics industry, focusing on the research and development of biological medical soft tissue repair materials, with strong technical barriers and product matrix advantages [1] Financial Performance - In Q3 2025, Aimeike reported revenue of 1.865 billion yuan, ranking second in the industry, while the industry leader, Huaxi Biological, achieved revenue of 3.163 billion yuan [2] - The company's net profit for the same period was 1.107 billion yuan, ranking first in the industry, with the second-ranked Jinbo Biological reporting a net profit of 565 million yuan [2] Financial Ratios - Aimeike's debt-to-asset ratio stood at 8.20% in Q3 2025, significantly lower than the industry average of 16.58%, indicating strong solvency [3] - The gross profit margin for the same period was 93.36%, higher than the industry average of 84.95%, reflecting robust profitability [3] Executive Compensation - Chairman Jian Jun's salary decreased from 2.5144 million yuan in 2023 to 2.49 million yuan in 2024, a reduction of 24,400 yuan [4] - General Manager Shi Yifeng's salary also saw a decrease from 2.955 million yuan in 2023 to 2.69 million yuan in 2024, a reduction of 265,000 yuan [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.10% to 56,300, while the average number of circulating A-shares held per shareholder increased by 0.10% to 3,704.54 [5] - Major shareholders, including Hong Kong Central Clearing Limited and various ETFs, have reduced their holdings [5] Business Highlights - Aimeike completed the acquisition of a controlling stake in South Korea's Regen Company, expanding its international market presence [5] - The company's subsidiary, Beijing Nobomin, received certification for Minoxidil topical solution, marking a significant milestone in product development [5] - Ongoing clinical trials for products like the second-generation implant line and the Sumei injection are expected to progress towards registration by the end of 2025 [5]

Core Viewpoint - Huaxi Biological is a leading company in the global hyaluronic acid industry, leveraging microbial fermentation and cross-linking technologies to establish a comprehensive business model from raw materials to end products [1] Group 1: Business Performance - In Q3 2025, Huaxi Biological achieved a revenue of 3.163 billion yuan, ranking first in the industry, surpassing the industry average of 2.108 billion yuan and the median of 1.865 billion yuan [2] - The main business segments include skin science innovation transformation (0.912 billion yuan, 40.34%), medical terminal products (0.673 billion yuan, 29.76%), and raw material products (0.626 billion yuan, 27.70%) [2] - The net profit for the same period was 0.252 billion yuan, ranking third in the industry, below the industry average of 0.641 billion yuan and the median of 0.565 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Huaxi Biological's debt-to-asset ratio was 16.29%, lower than the previous year's 18.82% and below the industry average of 16.58%, indicating good solvency [3] - The gross profit margin for the same period was 70.68%, down from 73.93% year-on-year and below the industry average of 84.95% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 3.79% to 31,300, while the average number of circulating A-shares held per household increased by 3.94% to 15,400 [5] - Major shareholders include various ETFs, with significant reductions in holdings noted for several funds [5] Group 4: Executive Compensation - The chairman and general manager Zhao Yan's compensation increased from 2.0249 million yuan in 2023 to 2.2282 million yuan in 2024, an increase of 203,300 yuan [4] Group 5: Future Outlook - Huachuang Securities projects net profits for 2025-2027 to be 0.458 billion, 0.618 billion, and 0.748 billion yuan respectively, with a target valuation of 30.89 billion yuan for 2026 [6] - Longjiang Securities anticipates EPS for 2025-2027 to be 0.99, 1.36, and 1.60 yuan per share, maintaining a "buy" rating [6]

证券代码：920982 证券简称：锦波生物 公告编号：2025-172 山西锦波生物医药股份有限公司 质量控制复核人时斌先生近三年不存在违反《中国注册会计师职业道德守 则》对独立性要求的情形，最近三年内未曾因执业行为受到过刑事处罚、行政 处罚、行政监管措施和自律处分。 山西锦波生物医药股份有限公司（以下简称"公司"）分别于 2025 年 4 月 19 日、2025 年 5 月 21 日召开第四届董事会第八次会议、2024 年年度股东会， 审议通过了《关于聘任中汇会计师事务所（特殊普通合伙）为公司 2025 年度审 计机构的议案》，同意续聘中汇会计师事务所（特殊普通合伙）（以下简称"中 汇"）为公司 2025 年度审计机构，具体内容请详见公司于 2025 年 4 月 21 日在 北京证券交易所官网（https://www.bse.cn）披露的《拟续聘 2025 年度会计师 事务所公告》（2025-029）。 近日，公司收到中汇出具的《关于变更质量控制复核人的告知函》。 一、本次质量控制复核人变更的基本情况 中汇作为公司 2025 年度审计机构，原指派陆加龙先生为质量控制复核人， 为公司提供 2025 年度财务报 ...

山西锦波生物医药股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日 召开第四届董事会第十七次会议，审议通过了《关于改选董事会相关专门委员 会委员的议案》，现将具体情况公告如下： 一、基本情况 鉴于公司董事人员发生变动，为保证董事会专门委员会顺利开展工作，根 据《公司法》等相关法律法规及《公司章程》的规定，结合董事会专门委员会 的职能职责、各位董事的行业背景及自身业务专长，公司拟对部分董事会专门 委员会委员进行改选，改选后各专门委员会的任期自本次董事会审议通过之日 起至第四届董事会届满之日止。 证券代码：920982 证券简称：锦波生物 公告编号：2025-171 山西锦波生物医药股份有限公司 关于改选部分董事会专门委员会委员的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 三、上述改选对公司的影响 本次对部分董事会专门委员会委员的改选符合相关法律法规、《公司章程》 及《董事会审计委员会工作细则》的有关规定，符合公司治理要求，不会对公 司经营产生不利影响。 四、备查文件 《山西锦波 ...

证券代码：920982 证券简称：锦波生物 公告编号：2025-169 （一）会议召开情况 1.会议召开时间：2025 年 10 月 27 日 2.会议召开地点：公司三楼会议室 3.会议召开方式：现场加通讯 4.发出董事会会议通知的时间和方式：2025 年 10 月 25 日以邮件方式发出 5.会议主持人：董事长杨霞女士 6.会议列席人员：薛芳琴、兰小宾 山西锦波生物医药股份有限公司 第四届董事会第十七次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 7.召开情况合法合规的说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关法 律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事陈镔、王玲玲、阎丽明、梁桐栋、邓泽林因出差或外地办公以通讯方式 参与表决。 二、议案审议情况 （一）审议通过《关于公司<2025 年第三季度报告>的议案》 1.议案内容： 根据《公司法》《 ...

Group 1 - The medical beauty sector experienced a decline of 0.14% on October 29, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] - Key stocks in the medical beauty sector showed varied performance, with Jinbo Biological rising by 7.46% and Ai Meike falling by 1.97% [1] Group 2 - The medical beauty sector saw a net outflow of 23.498 million yuan from main funds, while retail investors had a net inflow of 39.3117 million yuan [1] - Specific stock fund flows indicated that Huaxi Biological had a main fund inflow of 8.119 million yuan, while Ai Meike experienced a significant outflow of 29.5668 million yuan [2] - The overall trend showed that retail investors were more active in the sector, with a net inflow across several stocks despite the main and speculative funds pulling back [2]

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company is currently under short-term pressure but has a rich pipeline of new products and is expected to benefit from a potential recovery in industry demand [1][5] - The completion of the acquisition of Korean Regen Company strengthens the company's leading position in the medical beauty injection market and expands its international market presence [2] - The company has received certification for its minoxidil topical solution, which is aimed at treating male pattern baldness, and has successfully registered its first new cosmetic ingredient [2][3] Financial Performance - In Q3 2025, the company reported revenue of 566 million yuan, a year-on-year decrease of 21.3%, and a net profit attributable to the parent company of 304 million yuan, down 34.6% [1][7] - For the first three quarters of 2025, total revenue was 1.865 billion yuan, down 21.5% year-on-year, with a net profit of 1.093 billion yuan, a decrease of 31.0% [1] Product Pipeline and Development - The company has a robust pipeline with products like second-generation implant lines and injectable botulinum toxin expected to enter the registration phase by the end of 2025 [3] - Clinical trials for new products are ongoing, and successful launches could create new growth points for the company [3] Margin and Cost Analysis - The gross margin in Q3 2025 was recorded at 93.2%, a decrease of 1.4 percentage points year-on-year [4] - The report notes an increase in sales and management expense ratios due to rising labor and consulting service costs [4] Earnings Forecast and Valuation - Revenue forecasts for 2025-2027 have been adjusted downwards to 2.424 billion, 2.796 billion, and 3.083 billion yuan, respectively [5] - The net profit forecasts for the same period have also been revised down to 1.391 billion, 1.670 billion, and 1.945 billion yuan [5] - The target price is set at 182.16 yuan, based on a 33x PE ratio for 2026 [5]

（文章来源：证券时报网） 据iFinD统计，截至10月28日，沪深两市共有115股连续5日或5日以上获融资净买入。连续获融资净买入 天数最多的股票是中信博，均连续11个交易日获净买入；连续获融资净买入天数较多的还有神州泰岳、 岱美股份、旭升集团、锦波生物、上海艾录、乖宝宠物、胜宏科技、铜陵有色等股。 ...